Migraine with Brainstem Aura Accompanied by Disorders of Consciousness

References

• Bickerstaff E. Impairment of consciousness in migraine. Lancet. 1961;2(7211):1057–1059. doi:10.1016/s0140-6736(61)92538-7
   Google Scholar
• Lee C, Lance J. Migraine stupor. Headache. 1977;17(1):32–38. doi:10.1111/j.1526-4610.1977.hed1701032.x
   Web of Science ®Google Scholar
• Hockaday J. Basilar migraine in childhood. Dev Med Child Neurol. 1979;21(4):455–463. doi:10.1111/j.1469-8749.1979.tb01649.x
   Web of Science ®Google Scholar
• Smith M, Glass S. An adolescent girl with headache and syncope. J Adolesc Healthc. 1989;10(1):54–56. doi:10.1016/0197-0070(89)90049-1
   Web of Science ®Google Scholar
• Frequin S, Linssen W, Pasman J, Hommes O, Merx H. Recurrent prolonged coma due to basilar artery migraine. A case report. Headache. 1991;31(2):75–81. doi:10.1111/j.1526-4610.1991.hed3102075.x
   Web of Science ®Google Scholar
• Ganji S, Hellman S, Stagg S, Furlow J. Episodic coma due to acute basilar artery migraine: correlation of EEG and brainstem auditory evoked potential patterns. Clin EEG. 1993;24(1):44–48. doi:10.1177/155005949302400110
   Web of Science ®Google Scholar
• Muellbacher W, Mamoli B. Prolonged impaired consciousness in basilar artery migraine. Headache. 1994;34(5):282–285. doi:10.1111/j.1526-4610.1994.hed3405282.x
   Web of Science ®Google Scholar
• Maytal J, Libman R, Lustrin E. Basilar artery migraine and reversible imaging abnormalities. AJNR Am J Neuroradiol. 1998;19(6):1116–1119.
   Web of Science ®Google Scholar
• Li Q, Tan G, Zhou J. Basilar-type migraine with coma: case reports and literature review. Pain Med. 2011;12(4):654–656. doi:10.1111/j.1526-4637.2011.01080.x
   Web of Science ®Google Scholar
• Marsala S, Gioulis M. Basilar migraine mistaken for encephalitis. Neurolog Sci. 2012;33(1):213–214. doi:10.1007/s10072-011-0658-5
   Web of Science ®Google Scholar
• Inoue Y, Yabe T. Lomerizine therapy for the treatment of benign paroxysmal vertigo of childhood transitioning into atypical basilar migraine: a case report. Exp Ther Med. 2013;5(6):1573–1575. doi:10.3892/etm.2013.1035
   Web of Science ®Google Scholar
• Nesbitt A, Leschziner G. Migraine with brainstem aura presenting as recurrent hypersomnia (Kleine-Levin syndrome). Pract Neurol. 2016;16(5):402–405. doi:10.1136/practneurol-2016-001418
   Google Scholar
• Chou I, Lee I, Hong S. Basilar-type migraine: an overlooked cause of loss of consciousness in pediatric emergency rooms. Pediatr Neonatol. 2018;59(3):315–316. doi:10.1016/j.pedneo.2017.08.010
   Web of Science ®Google Scholar
• Rossi F, Gonzalez E, Rossi E, Tsakadze N. Exploding head syndrome as aura of migraine with brainstem aura: a case report. J Orofac Pain Headache. 2018;32(2):e34–e36. doi:10.11607/ofph.1950
   Web of Science ®Google Scholar
• Chirchiglia D, Chirchiglia P, Marotta R. A singular association of migraine with brainstem aura and Alice in Wonderland syndrome. Childs Nerv Syst. 2019;35(8):1435–1437. doi:10.1007/s00381-019-04170-8
   Web of Science ®Google Scholar
• Kirchmann M, Thomsen L, Olesen J. Basilar-type migraine: clinical, epidemiologic, and genetic features. Neurology. 2006;66(6):880–886. doi:10.1212/01.wnl.0000203647.48422.dd
   Web of Science ®Google Scholar
• Ying G, Fan W, Li N, et al. Clinical characteristics of basilar-type migraine in the neurological clinic of a university hospital. Pain Med. 2014;15(7):1230–1235. doi:10.1111/pme.12402
   Web of Science ®Google Scholar
• [No authors listed]. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1–211. doi:10.1177/0333102417738202
   PubMed Web of Science ®Google Scholar
• Chaudhry P, Friedman D. Hiccups as a migraine aura. Cephalalgia. 2015;35(9):831–834. doi:10.1177/0333102414560633
   Web of Science ®Google Scholar
• Bickerstaff E. Basilar artery migraine. Lancet. 1961;277(7167):15–17. doi:10.1016/S0140-6736(61)92184-5
   Google Scholar
• Kondziella D, Bender A, Diserens K, van Erp W. European academy of neurology guideline on the diagnosis of coma and other disorders of consciousness. Eur J Neurol. 2020;27(5):741–756. doi:10.1111/ene.14151
   PubMed Web of Science ®Google Scholar
• Nagata E. Recent advances in the elucidation of migraine pathophysiology. Rinsho Shinkeigaku. 2020;60(1):20–26. doi:10.5692/clinicalneurol.cn-001348
   Google Scholar
• Shevel E. The extracranial vascular theory of migraine–a great story confirmed by the facts. Headache. 2011;51(3):409–417. doi:10.1111/j.1526-4610.2011.01844.x
   PubMed Web of Science ®Google Scholar
• Charles A, Baca S. Cortical spreading depression and migraine. Nat Rev Neurol. 2013;9(11):637–644. doi:10.1038/nrneurol.2013.192
   PubMed Web of Science ®Google Scholar
• Cui Y, Kataoka Y, Watanabe Y. Role of cortical spreading depression in the pathophysiology of migraine. Neurosci Bull. 2014;30(5):812–822. doi:10.1007/s12264-014-1471-y
   PubMed Web of Science ®Google Scholar
• Ramachandran R. Neurogenic inflammation and its role in migraine. Semin Immunopathol. 2018;40(3):301–314. doi:10.1007/s00281-018-0676-y
   PubMed Web of Science ®Google Scholar
• Edvinsson L, Haanes K, Warfvinge K. Does inflammation have a role in migraine? Nat Rev Neurol. 2019;15(8):483–490. doi:10.1038/s41582-019-0216-y
   PubMed Web of Science ®Google Scholar
• Cavestro C, Ferrero M, Mandrino S, Di Tavi M, Rota E. Novelty in Inflammation and Immunomodulation in Migraine. Curr Pharm Des. 2019;25(27):2919–2936. doi:10.2174/1381612825666190709204107
   PubMed Web of Science ®Google Scholar
• Aguila M, Rebbeck T, Leaver A, et al. The association between clinical characteristics of migraine and brain GABA levels: an Exploratory Study. J Pain. 2016;17(10):1058–1067. doi:10.1016/j.jpain.2016.06.008
   PubMed Web of Science ®Google Scholar
• Requena I, Indakoetxea B, Lema C, Santos B, García-Castiñeira A, Arias M. Coma associated with migraine. Revista Neurologia. 1999;29(11):1048–1051.
   Web of Science ®Google Scholar
• Meylakh N, Marciszewski K, Di Pietro F, Macefield V, Macey P, Henderson L. Altered regional cerebral blood flow and hypothalamic connectivity immediately prior to a migraine headache. Cephalalgia. 2020;40(5):448–460. doi:10.1177/0333102420911623
   PubMed Web of Science ®Google Scholar
• Demarquay G, Ducros A, Montavont A, Mauguiere F. Migraine with brainstem aura: why not a cortical origin? Cephalalgia. 2018;38(10):1687–1695. doi:10.1177/0333102417738251
   Web of Science ®Google Scholar
• Sutherland H, Griffiths L. Genetics of migraine: insights into the molecular basis of migraine disorders. Headache. 2017;57(4):537–569. doi:10.1111/head.13053
   PubMed Web of Science ®Google Scholar
• Rasmussen A, Kogelman L, Kristensen D, Chalmer M, Olesen J, Hansen T. Functional gene networks reveal distinct mechanisms segregating in migraine families. Brain. 2020;143(10):awaa242. doi:10.1093/brain/awaa242
   Web of Science ®Google Scholar
• Karsan N, Goadsby P. Biological insights from the premonitory symptoms of migraine. Nat Rev Neurol. 2018;14(12):699–710. doi:10.1038/s41582-018-0098-4
   PubMed Web of Science ®Google Scholar
• Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia. 2013;33(9):629–808. doi:10.1177/0333102413485658
   PubMed Web of Science ®Google Scholar
• Beukers R, Roos Y. Pontine capillary telangiectasia as visualized on MR imaging causing a clinical picture resembling basilar-type migraine: a case report. J Neurol. 2009;256(10):1775–1777. doi:10.1007/s00415-009-5204-5
   Web of Science ®Google Scholar
• Cannas A, Solla P, Mascia M, et al. Medulloblastoma induces unusual headache with clinical picture of basilar-type migraine complicated by ischaemic infarcts. Cephalalgia. 2006;26(10):1238–1241. doi:10.1111/j.1468-2982.2006.01176.x
   Web of Science ®Google Scholar
• Huang L, Yu C, Wang B, Zhang H, Li L, Wang Y. Vertebrobasilar dolichoectasia causing a presentation resembling basilar-type migraine. Clin Neurol Neurosurg. 2013;115(6):784–786. doi:10.1016/j.clineuro.2012.07.007
   Web of Science ®Google Scholar
• Huang P, Yang F, Chang C, Yang C. Targeting the 5-HT and 5-HT receptors for acute migraine treatment. Prog Brain Res. 2020;255:99–121. doi:10.1016/bs.pbr.2020.05.010
   Web of Science ®Google Scholar
• Negro A, Koverech A, Martelletti P. Serotonin receptor agonists in the acute treatment of migraine: a review on their therapeutic potential. J Pain Res. 2018;11:515–526. doi:10.2147/jpr.S132833
   PubMed Web of Science ®Google Scholar
• Vgontzas A, Burch R. episodic migraine with and without aura: key differences and implications for pathophysiology, management, and assessing risks. Curr Pain Headache Rep. 2018;22(12):78. doi:10.1007/s11916-018-0735-z
   Web of Science ®Google Scholar
• Mathew PG, Klein BC. Getting to the heart of the matter: migraine, triptans, DHE, ditans, CGRP antibodies, First/Second-Generation gepants, and cardiovascular risk. Headache. 2019;59(8):1421–1426. doi:10.1111/head.13601
   PubMed Web of Science ®Google Scholar
• Curto M, Cipolla F, Cisale G, et al. Profiling lasmiditan as a treatment option for migraine. Expert Opin Pharmacother. 2020;21(2):147–153. doi:10.1080/14656566.2019.1694004
   PubMed Web of Science ®Google Scholar
• Lamb Y. Lasmiditan: first approval. Drugs. 2019;79(18):1989–1996. doi:10.1007/s40265-019-01225-7
   PubMed Web of Science ®Google Scholar
• Yang Y, Sun Y, Gao B, Wang Z, Chen Z, Wang Z. Lasmiditan for acute treatment of migraine in adults: a systematic review and meta-analysis of Randomized Controlled Trials. CNS Drugs. 2020;34(10):1015–1024. doi:10.1007/s40263-020-00753-1
   PubMed Web of Science ®Google Scholar
• Hamann T, Kamm K, Kropp P, Rimmele F, Jürgens T. Migraine prophylaxis-all just antibodies?: medical and nonmedical migraine preventive treatment in times of CGRP antibodies. Schmerz. 2020;34(6):476–485. doi:10.1007/s00482-020-00500-x
   Web of Science ®Google Scholar
• Kristoffersen E, Børte S, Hagen K, Zwart J, Winsvold B. Migraine, obesity and body fat distribution - a population-based study. J headache Pain. 2020;21(1):97. doi:10.1186/s10194-020-01163-w
   PubMed Web of Science ®Google Scholar
• Oskoui M, Pringsheim T, Billinghurst L, et al. Practice guideline update summary: pharmacologic treatment for pediatric migraine prevention: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2019;93(11):500–509. doi:10.1212/wnl.0000000000008105
   PubMed Web of Science ®Google Scholar
• Aydin H, Bucak I, Geyik M. Vitamin B12 and folic acid levels in pediatric migraine patients. Acta Neurol Belg. 2020. doi:10.1007/s13760-020-01491-3
   Web of Science ®Google Scholar
• Meßlinger K. Pathophysiological role of calcitonin gene-related peptide (CGRP) in migraine and cluster headache. Schmerz. 2020;34(2):181–187. doi:10.1007/s00482-020-00448-y
   Web of Science ®Google Scholar
• Goadsby P, Dodick D, Ailani J, et al. Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b/3 trial. Lancet Neurol. 2020;19(9):727–737. doi:10.1016/s1474-4422(20)30234-9
   PubMed Web of Science ®Google Scholar
• Charles A, Pozo-Rosich P. Targeting calcitonin gene-related peptide: a new era in migraine therapy. Lancet. 2019;394(10210):1765–1774. doi:10.1016/s0140-6736(19)32504-8
   PubMed Web of Science ®Google Scholar
• Ferrari M, Diener H, Ning X, et al. Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, Phase 3b trial. Lancet. 2019;394(10203):1030–1040. doi:10.1016/s0140-6736(19)31946-4
   PubMed Web of Science ®Google Scholar
• Hong P, Tan T, Liu Y, Xiao J. Gepants for abortive treatment of migraine: a network meta-analysis. Brain Behav. 2020;10(8):e01701. doi:10.1002/brb3.1701
   PubMed Web of Science ®Google Scholar
• Moreno-Ajona D, Perez-Rodriguez A, Goadsby PJ. Gepants, calcitonin-gene-related peptide receptor antagonists: what could be their role in migraine treatment? Curr Opin Neurol. 2020;33(3):309–315. doi:10.1097/WCO.0000000000000806
   PubMed Web of Science ®Google Scholar
• Curto M, Capi M, Cipolla F, Cisale GY, Martelletti P, Lionetto L. Ubrogepant for the treatment of migraine. Expert Opin Pharmacother. 2020;21(7):755–759. doi:10.1080/14656566.2020.1721462
   PubMed Web of Science ®Google Scholar
• Dodick DW, Lipton RB, Ailani J, et al. Ubrogepant for the treatment of migraine. N Engl J Med. 2019;381(23):2230–2241. doi:10.1056/NEJMoa1813049
   PubMed Web of Science ®Google Scholar
• Dhir A. Ubrogepant to treat migraine. Drugs Today (Barc). 2020;56(7):459–467. doi:10.1358/dot.2020.56.7.3157311
   Web of Science ®Google Scholar
• Lipton RB, Dodick DW, Ailani J, et al. Effect of ubrogepant vs placebo on pain and the most bothersome associated symptom in the acute treatment of migraine: the ACHIEVE II Randomized Clinical Trial. JAMA. 2019;322(19):1887–1898. doi:10.1001/jama.2019.16711
   PubMed Web of Science ®Google Scholar
• Ailani J, Lipton RB, Hutchinson S, et al. Long-term safety evaluation of ubrogepant for the acute treatment of migraine: phase 3, randomized, 52-Week Extension Trial. Headache. 2020;60(1):141–152. doi:10.1111/head.13682
   PubMed Web of Science ®Google Scholar
• Yang Y, Chen M, Sun Y, Gao B, Chen Z, Wang Z. Safety and efficacy of ubrogepant for the acute treatment of episodic migraine: a meta-analysis of Randomized Clinical Trials. CNS Drugs. 2020;34(5):463–471. doi:10.1007/s40263-020-00715-7
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Blumenfeld AM, Lipton RB, et al. Time course of efficacy of ubrogepant for the acute treatment of migraine: clinical implications. Cephalalgia. 2020:333102420970523. doi:10.1177/0333102420970523
   Web of Science ®Google Scholar
• Dodick DW, Lipton RB, Ailani J, et al. Ubrogepant, an acute treatment for migraine, improved patient-reported functional disability and satisfaction in 2 single-attack phase 3 Randomized Trials, ACHIEVE I and II. Headache. 2020;60(4):686–700. doi:10.1111/head.13766
   PubMed Web of Science ®Google Scholar
• Negro A, Martelletti P. Rimegepant for the treatment of migraine. Drugs Today (Barc). 2020;56(12):769–780. doi:10.1358/dot.2020.56.12.3211624
   PubMed Web of Science ®Google Scholar
• Croop R, Goadsby PJ, Stock DA, et al. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. Lancet. 2019;394(10200):737–745. doi:10.1016/S0140-6736(19)31606-X
   PubMed Web of Science ®Google Scholar
• Gao B, Yang Y, Wang Z, et al. Efficacy and safety of rimegepant for the acute treatment of migraine: evidence from Randomized Controlled Trials. Front Pharmacol. 2019;10:1577. doi:10.3389/fphar.2019.01577
   Web of Science ®Google Scholar
• Lipton RB, Croop R, Stock EG, et al. Rimegepant, an oral calcitonin gene-related peptide receptor antagonist, for migraine. N Engl J Med. 2019;381(2):142–149. doi:10.1056/NEJMoa1811090
   PubMed Web of Science ®Google Scholar
• Croop R, Lipton RB, Kudrow D, et al. Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial. Lancet. 2021;397(10268):51–60. doi:10.1016/S0140-6736(20)32544-7
   PubMed Web of Science ®Google Scholar
• Sacco S, Bendtsen L, Ashina M, et al. European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. J Headache Pain. 2019;20(1):6. doi:10.1186/s10194-018-0955-y
   PubMed Web of Science ®Google Scholar
• Berman G, Croop R, Kudrow D, et al. Safety of rimegepant, an oral CGRP receptor antagonist, plus CGRP monoclonal antibodies for migraine. Headache. 2020;60(8):1734–1742. doi:10.1111/head.13930
   PubMed Web of Science ®Google Scholar
• de Vries T, Al-Hassany L, MaassenVanDenBrink A. Evaluating rimegepant for the treatment of migraine. Expert Opin Pharmacother. 2021;1–7. doi:10.1080/14656566.2021.1895749
   Web of Science ®Google Scholar
• Pavelek Z, Soucek O, Krejsek J, et al. The role of the immune system and the biomarker CD3 + CD4 + CD45RA-CD62L- in the pathophysiology of migraine. Sci Rep. 2020;10(1):12277. doi:10.1038/s41598-020-69285-4
   Web of Science ®Google Scholar
• Akda GT, Uca AU. Cystatin C as a potential biomarker to evaluate migraine. Arq Neuropsiquiatr. 2020;78(6):337–341. doi:10.1590/0004-282X20200005
   Web of Science ®Google Scholar
• Cernuda-Morollon E, Larrosa D, Ramon C, Vega J, Martinez-Camblor P, Pascual J. Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine. Neurology. 2013;81(14):1191–1196. doi:10.1212/WNL.0b013e3182a6cb72
   PubMed Web of Science ®Google Scholar
• Ramon C, Cernuda-Morollon E, Pascual J. Calcitonin gene-related peptide in peripheral blood as a biomarker for migraine. Curr Opin Neurol. 2017;30(3):281–286. doi:10.1097/WCO.0000000000000440
   PubMed Web of Science ®Google Scholar
• Fan PC, Kuo PH, Lee MT, Chang SH, Chiou LC. Plasma calcitonin gene-related peptide: a potential biomarker for diagnosis and therapeutic responses in pediatric migraine. Front Neurol. 2019;10:10. doi:10.3389/fneur.2019.00010
   PubMed Web of Science ®Google Scholar
• Yuasa N, Nagata E, Fujii N, Ito M, Tsukamoto H, Takizawa S. Serum apolipoprotein E may be a novel biomarker of migraine. PLoS One. 2018;13(1):e0190620. doi:10.1371/journal.pone.0190620
   PubMed Web of Science ®Google Scholar
• Kheirollahi M, Kazemi M, Amini G, et al. Expression of prostaglandin I2 (prostacyclin) receptor in blood of migraine patients: a potential biomarker. Adv Biomed Res. 2015;4(1):121. doi:10.4103/2277-9175.158030
   Google Scholar
• Cernuda-Morollon E, Martinez-Camblor P, Alvarez R, Larrosa D, Ramon C, Pascual J. Increased VIP levels in peripheral blood outside migraine attacks as a potential biomarker of cranial parasympathetic activation in chronic migraine. Cephalalgia. 2015;35(4):310–316. doi:10.1177/0333102414535111
   PubMed Web of Science ®Google Scholar
• Celikbilek A, Sabah S, Tanik N, Ak H, Atalay T, Yilmaz N. Is serum S100B protein an useful biomarker in migraine? Neurol Sci. 2014;35(8):1197–1201. doi:10.1007/s10072-014-1679-7
   Web of Science ®Google Scholar
• Lee MJ, Lee SY, Cho S, Kang ES, Chung CS. Feasibility of serum CGRP measurement as a biomarker of chronic migraine: a critical reappraisal. J Headache Pain. 2018;19(1):53. doi:10.1186/s10194-018-0883-x
   PubMed Web of Science ®Google Scholar